Long Term Acid Suppressant Medications (ppi’s): Concerns and Care

Apr 12 18:00 2015 Sanjiv Haribhakti Print This Article

Maintenance antisecretory acid therapy (PPI’s) are used in many patients, particularly those with gastroesophageal reflux disease(GERD). With the long-term use of any medication, drug safety becomes an important issue. Acid (HCl) is normally secreted into the gastric lumen, where it serves to both digest dietary protein and maintain a sterile environment by removing ingested bacterias. Proton pump inhibitors (PPIs) are strong acid suppressants, and thus long term usage has raised several issues which shall be discussed in this article.

 

Maintenance antisecretory acid therapy (PPI’s) are used in many patients,Guest Posting particularly those with gastroesophageal reflux disease(GERD). With the long-term use of any medication, drug safety becomes an important issue. Acid (HCl) is normally secreted into the gastric lumen, where it serves to both digest dietary protein and maintain a sterile environment by removing ingested bacterias. Proton pump inhibitors (PPIs) are strong acid suppressants, and thus long term usage has raised several issues which shall be discussed in this article.

The three main concerns regarding the long-term usage of proton pump inhibitors (PPIs) include :

  1. Risk of infectious complications – including Pneumonias, Cl difficile diarrhoeas

  2. Malabsorption of Iron, Vitamin B12, Magnesium and Metabolic bone disease

  3. Hypergastrinemia, Gastric carcinoids and Atrophic Gastritis

Other concerns include acute interstitial nephritis (kidney disease) and drug interactions particularly reducing the effect of Clopidogrel, which is used in coronary stented patients to reduce the risk of stent blockage.

InfectionsA concern with any form of gastric acid inhibition is an increased risk of enteric infections since gastric acid normally protects against these infections. In addition, a reduction in gastric acid secretion permits bacteria to more easily colonize the upper gastrointestinal tract, which may predispose to pneumonia.

Clostridium difficile and other enteric infectionsThe best documented association of PPI use with enteric infections has been with C. difficile diarrhea, even in patients not exposed to antibiotics(1-7). C. difficile is an anaerobic organism that sporulates; acid-resistant spores are presumed to be the major vector of disease transmission. Three meta-analyses of observational studies have demonstrated an increased risk of C. difficile infections in patients treated with PPIs(8-10). A 2012 meta-analysis of 42 observational studies that included 313,000 patients found that PPI use was significantly associated with an increased risk of both incident and recurrent C. difficile infection(9).

The US Food and Drug Administration (FDA) has issued a safety alert encouraging providers to consider a diagnosis of C. difficile-associated disease in PPI users with persistent diarrhea(11). Given the potential risk of C. difficile infection, the FDA has also recommended that providers prescribe the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.

Associations with other enteric infections, including Campylobacter and Salmonella, have also been reported(12-15), but the risk is uncertain(16).

PneumoniaThe risk of pneumonia in PPI users may be increased due to a reduction in gastric acid secretion, permitting bacteria to more easily colonize the upper gastrointestinal tract. The increased risk has been seen with both community-acquired pneumonia (CAP) and health care associated pneumonia (HCAP)(17-19). A meta-analysis of 31 studies found that patients taking PPIs or H2 receptor antagonists (H2RAs) were at increased risk for pneumonia(20).

MalabsorptionConcern has been expressed regarding the effects of long-term PPI use on iron and vitamin B12 absorption, though any effects are generally mild, clinically insignificant, and addressed by supplement therapy(21). On the other hand, magnesium and calcium malabsorption may be bigger problems, predisposing to hypomagnesia and metabolic bone disease.

Magnesium absorptionHypomagnesemia due to reduced intestinal absorption has been described with PPI use(22). In March 2011, the FDA issued a safety alert warning providers of the risk of hypomagnesemia in patients who have been on PPIs long-term (generally longer than one year)(23).

Hip fracture and calcium malabsorptionLong-term use of PPIs may influence bone metabolism. Hypochlorhydria could theoretically reduce calcium absorption(24) and inhibit osteoclastic activity(25,26), thereby decreasing bone density. A case-control trial suggested that long-term use of PPIs was associated with a slightly increased risk of hip fractures in those older than 50 years of age and that the magnitude of the risk increase was proportional to both PPI dose and duration of therapy(27). A meta-analysis that included 11 cohort and case-control studies examined the risk of fractures associated with PPI use(28). The 11 studies included 1,084,560 patients with 62,210 PPI users, 71,339 patients with hip fractures, 161,179 patients with any-site fractures, and 5728 patients with spine fractures. The risk of hip fracture was increased among PPI users compared with nonusers. There was also an increased risk of spine and any-site fracture. The FDA has mandated revised safety information on all PPIs about a possible increased risk of fractures of the hip, wrist, and spine with the use of these medications(29). The FDA also recommends that healthcare professionals who prescribe PPIs consider whether a lower dose or shorter duration of therapy would adequately treat the patient’s condition.

Vitamin B12 malabsorptionLong-term therapy with omeprazole has been associated with vitamin B12 malabsorption(30,31). Thus, it is reasonable to assess vitamin B12 levels periodically (eg, annually) in patients who are on long-term treatment with PPIs(32).

Iron malabsorptionGastric acid plays a role in the absorption of nonheme iron, and the use of PPIs has been associated with decreased iron absorption(21,33-35). However, in most cases the decreased absorption does not appear to be of clinical significance. One exception may be in patients who require oral iron supplementation(35,36).

HypergastrinemiaAn initial concern with omeprazole was the induction of hypergastrinemia and gastric carcinoid tumors in rats, changes also demonstrated with chronic ranitidine exposure(37). While patients treated with omeprazole for up to 11 years have shown some enterochromaffin cell hyperplasia, no dysplasia or neoplastic changes have been observed(38).

The clinical significance of other theoretical risks related to hypergastrinemia (such as colon cancer) has not been established. One study found no increased risk of colon cancer in long-term users of a PPI(39).

Atrophic gastritisPatients receiving maintenance therapy have a propensity to develop chronic atrophic gastritis. Although the risk of atrophic gastritis in this context remains unclear, it could theoretically lead to an increased incidence of gastric cancer. In one study, for example, atrophy developed in over 30 percent of patients after omeprazole therapy for a five-year period(40). However, since the omeprazole-treated patients developed atrophy only in the presence of a concomitant H. pylori infection, it was suggested that only the H. pylori infected group was at risk. We do not routinely test for H. pylori in patients who require long-term therapy with a proton pump inhibitor since the risk of atrophic gastritis is small and, in the uncommon patient who develops it, the clinical consequences are uncertain.

Acute interstitial nephritisPPIs have been associated with acute interstitial nephritis (AIN)(41-44). Drug-induced AIN is not dose-dependent, and recurrence or exacerbation can occur with a second exposure to the same or a related drug.

Drug interactionsClinically important drug interactions with PPIs are rare. However, some data suggest decreased activation of clopidogrel when used in conjunction with omeprazole on the basis of a shared hepatic metabolic pathway. Other mechanisms by which PPIs might negatively impact cardiovascular outcomes have also been proposed(45). In 2009, the US Food and Drug Administration (FDA) concluded that patients taking clopidogrel should consult with their clinician if they are taking or considering taking a PPI, including over-the-counter PPI preparations(46-47). PPIs, with the exception of pantoprazole, have been associated with reduced effectiveness of clopidogrel and a resulting 40% increased risk of coronary stent occlusions(48).

DISCONTINUING PROTON PUMP INHIBITORSMany patients with gastroesophageal reflux disease (GERD) and dyspepsia are maintained on proton pump inhibitors (PPIs), but some concerns have been expressed regarding the long-term safety of these medications, as well as potentially important drug interactions. As a result, some asymptomatic patients who do not have other indications for being on a PPI may be candidates for having their PPI discontinued, though many relapse once the medication is stopped. Previous studies have demonstrated rebound gastric acid hypersecretion following the discontinuation of PPIs in patients managed for prolonged periods of time with these agents. As discussed below, no specific method for discontinuing the use of PPIs has been proven effective, and no approach is universally accepted(49,50). Moreover, despite the definition of “prolonged therapy” being likewise unclear, patients treated for a period of six months might be considered candidates for dose tapering. The following are general guidelines that may be employed when stopping a PPI:

  • Patients with GERD or dyspepsia are considered for a taper after being asymptomatic for a minimum of three months.

  • Patients treated for acute duodenal and gastric ulcers or as part of a course of treatment for H. pylori for four to eight weeks do not require a taper.

    In summary, several health related hazards have been identified with a prolonged use of PPI’s, and the the key is to use PPIs only when clearly indicated, and to reassess continued use, so that long-term therapy is used judiciously(51).

REFERENCES

  1. Naggie S, Miller BA, Zuzak KB, et al. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011; 124:276.e1.

  2. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170:784.

  3. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103:2308.

  4. Vaishnavi C. Established and potential risk factors for Clostridum difficile infection. Indian J Med Microbiol 2009; 27:289.

  5. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171:33.

  6. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54:243.

  7. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989.

  8. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047.

  9. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107:1011.

  10. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107:1001.

  11. FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm.

  12. Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. BMJ 1996; 312:414.

  13. Kader SA, Mansour AM, Mohran Z, et al. A study on the relation between proton pump inhibitor and gastric giardiasis. J Egypt Soc Parasitol 1998; 28:149.

  14. Reynaert H, Fernandes E, Bourgain C, et al. Proton-pump inhibition and gastric giardiasis: a causal or casual association? J Gastroenterol 1995; 30:775.

  15. García Rodríguez LA, Ruigómez A, Panés J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5:1418.

  16. Garcia Rodríguez LA, Ruigómez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology 1997; 8:571.

  17. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167:950.

  18. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955.

  19. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149:391.

  20. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183:310.

  21. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009; 104 Suppl 2:S5.

  22. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012; 36:405.

  23. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245275.htm

  24. Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985; 313:70.

  25. Tuukkanen J, Väänänen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 1986; 38:123.

  26. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53:21.

  27. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296:2947.

  28. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011; 124:519.

  29. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213321.htm

  30. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994; 120:211.

  31. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013; 310:2435.

  32. Laine L, Ahnen D, McClain C, et al. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000; 14:651.

  33. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007; 56:1291.

  34. Sarzynski E, Puttarajappa C, Xie Y, et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci 2011; 56:2349.

  35. Ajmera AV, Shastri GS, Gajera MJ, Judge TA. Suboptimal response to ferrous sulfate in iron-deficient patients taking omeprazole. Am J Ther 2012; 19:185.

  36. Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 2004; 97:887.

  37. Freston JW. Omeprazole, hypergastrinemia, and gastric carcinoid tumors. Ann Intern Med 1994; 121:232.

  38. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118:661.

  39. van Soest EM, van Rossum LG, Dieleman JP, et al. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol 2008; 103:966.

  40. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334:1018.

  41. Sampathkumar K, Ramalingam R, Prabakar A, Abraham A. Acute interstitial nephritis due to proton pump inhibitors. Indian J Nephrol 2013; 23:304.

  42. Ra A, Tobe SW. Acute interstitial nephritis due to pantoprazole. Ann Pharmacother 2004; 38:41.

  43. Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006; 4:597.

  44. Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis 2014; 64:558.

  45. Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013; 128:845.

  46. Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Available on the US Food and Drug Administration (FDA) web site: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm190848.htm

  47. FDA’s MedWatch Safety Alerts: November 2009. Plavix and Prilosec Drug Interaction. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm192103.htm#PlavixandPrilosecDrugInteraction.

  48. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. 2009;180:713–718. [PMC free article] [PubMed]

  49. Björnsson E, Abrahamsson H, Simrén M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24:945.

  50. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121:1095

  51. Alan BR Thomson, Michel D Sauve, Narmin Kassam, and Holly Kamitakahara. Safety of the long-term use of proton pump inhibitors World J Gastroenterol. 2010 May 21; 16(19): 2323–2330.

 

Source :- https://sanjivharibhakti.wordpress.com/2015/03/29/long-term-acid-suppressant-medications-ppis-concerns-and-care/

 

Source: Free Guest Posting Articles from ArticlesFactory.com

About Article Author

Sanjiv Haribhakti
Sanjiv Haribhakti

Dr. Sanjiv Pravin Haribhakti is a well known, senior and qualified GI surgeon from Ahmedabad, practicing for 17 years. He is a chairman of Haribhakti Education Foundation and having credit of 22 published papers in National & International indexed journals. Dr. Sanjiv Haribhakti is First M.Ch. GI surgeon of Western India.

 

View More Articles